Bend Research, Inc.

Glialogix, Inc.

Pfizer Corporation

Dow Global Technolgoies LLC

Ebara Corporation

Catalytica, Inc.

Cerecin Inc.

Pfizer Products Inc.

David Keith Lyon

Dwayne Thomas Friesen

Warren Kenyon Miller

Douglas Alan Lorenz

Walter Christian Babcock

Daniel Tod Smithey

Mark Wade Moore

Thaddeus Cromwell Reeder

Scott B McCray

Daniel Elmont Dobry

Marshall David Crew

Leah Elizabeth Appel

Rodney James Ketner

David Thomas Vodak

David J Edlund

James William West

Ravi Mysore Shanker

Corey Bloom

Roderick Jack Ray

Scott Max Herbig

Julian B Lo

Michael Mark Morgen

Bruno Caspar Hancock

James Mathew Mullin

David D Newbold

Samuel T Henderson

Avinash G Thombre

Joshua R Shockey

William Brett Caldwell

James Blair West

Devon B DuBose

Delores R Sidwell

Richard G Finke

Daichi Sakashita

Matthew Jarud Shaffer

Aaron Badenoch

Noritaka Mizuno

Avinash Govind Thombre

Christi Lynn Hostetler

Craig A Sather

Taryn Boivin

Timothy A Hagen

Timothy J McDermott

James Alan Shriver Nightingale

Jennifer Hsing-Chung Chu

Devon B Dubose

Matthew J Shaffer

Timothy Arthur Hagen

Scott Baldwin Mccray

Julian Belknap Lo

James Matthew Mullin

Timothy Joseph Mc Dermott

This invention relates to high drug load compositions of medium chain triglycerides (MCT), and to methods for treatment with such compositions at amounts effective to elevate ketone body concentrations so as to treat conditions associated with reduced neuronal metabolism, for example Alzheimer's disease.

Pharmaceutical compositions having high drug loadings of medium chain triglycerides and methods related thereto

In one embodiment, the present application discloses methods of treating diseases and disorders with sulfasalazine and pharmaceutical formulations of sulfasalazine where the bioavailability of the sulfasalazine is increased. In another embodiment, the present application also provides dosing regimens for treating neurodegenerative diseases and disorders with compositions comprising sulfasalazine.

Compositions and methods for the treatment of neurodegenerative and other diseases

Pharmaceutical compositions are provided comprising an active agent and a dextran polymer derivative. The compositions include from 0.01 to 99 wt % of an active agent and from 1 to 99.99 wt % of a dextran polymer derivative. The dextran polymer derivative is selected from dextran acetate, dextran propionate, dextran succinate, dextran acetate propionate, dextran acetate succinate, dextran propionate succinate, dextran acetate propionate succinate, and mixtures thereof.

Pharmaceutical compositions of dextran polymer derivatives

Pharmaceutical compositions of a low-solubility drug and lower alkanoate-, phthalate- and trimellitate esters of hydroxypropyl methyl cellulose and lower alkanoate- and succinate esters of cellulose and methyl cellulose are disclosed that provide enhanced concentrations of the drug in a use environment.

Pharmaceutical compositions with enhanced performance

Disclosed are polymers of hydroxypropyl methyl cellulose acetate succinate (HPMCAS) with unique degrees of substitution of hydroxypropoxy, methoxy, acetyl, and succinoyl groups. When used in making compositions comprising a low-solubility active agent and such polymers, the polymers provide increased aqueous concentrations and/or improved physical stability of the active agent.

Hydroxypropyl methyl cellulose acetate succinate with enhanced acetate and succinate substitution

Disclosed are polymers of hydroxypropyl methyl cellulose acetate succinate (HPMCAS) and hydroxypropyl methyl cellulose acetate (HPMCA) with unique degrees of substitution of hydroxypropoxy, methoxy, acetyl, and succinoyl groups. When used in making compositions comprising a low-solubility drug and such polymers, the polymers provide enhanced aqueous concentrations and/or improved physical stability.

A secondary drying process is disclosed for removing residual solvent from drug-containing particles that have been formed by solvent-based processes.

Drying of drug-containing particles

A solid amorphous dispersion comprises a cholesteryl ester transfer protein (CETP) inhibitor, an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMG-CoA reductase inhibitor), and a concentration enhancing polymer. At least a major portion of the CETP inhibitor in the dispersion is amorphous. The solid amorphous dispersion provides concentration-enhancement of the CETP inhibitor when administered to an aqueous use environment.

Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors and HMG-CoA reductase

Pharmaceutical compositions comprising a poorly water soluble ionizable drug, a cationic species and a dispersion polymer are disclosed, together with a process for forming the compositions. The neutral form of the drug has (i) a solubility of less than 1 mg/ml, in aqueous solution at a pH between 6 and 7, (ii) a solubility of less than 20 mg/mL in a volatile organic solvent, and (iii) an acidic pKa value of greater than 5. At least 90 wt % of the drug in the solid dispersion being in a non-crystalline form. The drug, the cationic species, and the dispersion polymer constitute at least 80 wt % of the solid dispersion.

Spray dried formulation

Growing community of inventors

Bend, OR, United States of America

David Keith Lyon